{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:04:04Z","timestamp":1779771844974,"version":"3.53.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ahj.2025.07.072","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:01:46Z","timestamp":1754492506000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Medicare coverage gap status, adherence to oral anticoagulation, and stroke rates in patients with atrial fibrillation"],"prefix":"10.1016","volume":"291","author":[{"given":"Josephine","family":"Harrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4726-157X","authenticated-orcid":false,"given":"Rohin K.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Carnicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley H.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Pokorney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Melloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.07.072_bib0001","unstructured":"What is the Medicare donut hole. 2025 [cited 2025 June 11];Available from: https:\/\/www.ncoa.org\/article\/the-medicare-part-d-donut-hole-what-you-need-to-know\/"},{"key":"10.1016\/j.ahj.2025.07.072_bib0002","first-page":"1133","article-title":"Medicare cuts cost of 10 common drugs covered by part D","volume":"332","author":"Anderer","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2025.07.072_bib0003","year":"2023","journal-title":"ASPE"},{"key":"10.1016\/j.ahj.2025.07.072_bib0004","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.041974","article-title":"Cost-related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017","volume":"140","author":"Khera","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.07.072_bib0005","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.18553\/jmcp.2016.22.11.1338","article-title":"Impact of out-of-pocket pharmacy costs on branded medication adherence among patients with type 2 diabetes","volume":"22","author":"Bibeau","year":"2016","journal-title":"JMCP"},{"key":"10.1016\/j.ahj.2025.07.072_bib0006","first-page":"302","article-title":"The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective","volume":"19","author":"Casciano","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.ahj.2025.07.072_bib0007","first-page":"430","article-title":"Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy","volume":"24","author":"Deshpande","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ahj.2025.07.072_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2016.03.212","article-title":"Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke","volume":"215","author":"Alberts","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2025.07.072_bib0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40256-019-00371-3","article-title":"Adherence to anticoagulation and risk of stroke among Medicare beneficiaries newly diagnosed with atrial fibrillation","volume":"20","author":"Hernandez","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ahj.2025.07.072_bib0010","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/03007995.2018.1428543","article-title":"Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants","volume":"34","author":"Deshpande","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ahj.2025.07.072_bib0011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12872-017-0671-6","article-title":"Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration","volume":"17","author":"Borne","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ahj.2025.07.072_bib0012","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ahj.2014.03.023","article-title":"Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration","volume":"167","author":"Shore","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2025.07.072_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003074","article-title":"Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2025.07.072_bib0014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ahj.2020.12.010","article-title":"Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: a population-based cohort study","volume":"233","author":"Rome","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2025.07.072_bib0015","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","article-title":"Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med Care"},{"key":"10.1016\/j.ahj.2025.07.072_bib0016","doi-asserted-by":"crossref","first-page":"w305","DOI":"10.1377\/hlthaff.28.2.w305","article-title":"The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits","volume":"28","author":"Schneeweiss","year":"2009","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ahj.2025.07.072_bib0017","article-title":"Effects of Medicare Part D coverage gap on medication adherence","volume":"19","author":"Yuting Zhang","year":"2013","journal-title":"Am J Managed Care"},{"key":"10.1016\/j.ahj.2025.07.072_bib0018","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/qje\/qjae015","article-title":"The health costs of cost sharing","volume":"139","author":"Chandra","year":"2024","journal-title":"Q J Econ"},{"key":"10.1016\/j.ahj.2025.07.072_bib0019","unstructured":"RxSaver [Internet]. Warfarin coupons & prices. [cited 2021 Nov 12];Available from: https:\/\/www.rxsaver.com\/drugs\/warfarin-sodium\/coupons"},{"key":"10.1016\/j.ahj.2025.07.072_bib0020","article-title":"Closing the Medicare Part D coverage gap: trends, recent changes, and what\u2019s ahead","author":"Damico","year":"2018","journal-title":"KFF"},{"key":"10.1016\/j.ahj.2025.07.072_bib0021","unstructured":"Medicare Interactive. The part D donut hole. [cited 2021 Nov 12];Available from: https:\/\/www.medicareinteractive.org\/get-answers\/medicare-prescription-drug-coverage-part-d\/medicare-part-d-costs\/the-part-d-donut-hole"},{"key":"10.1016\/j.ahj.2025.07.072_bib0022","unstructured":"Phases of part D coverage. Medicare Interact. [cited 2025 June 11];Available from: https:\/\/www.medicareinteractive.org\/understanding-medicare\/medicare-prescription-drug-coverage-part-d\/medicare-part-d-costs\/phases-of-part-d-coverage"},{"key":"10.1016\/j.ahj.2025.07.072_bib0023","unstructured":"Medicare drug price negotiation program: negotiated prices for initial price applicability year 2026 | CMS [cited 2025 June 11];Available from: https:\/\/www.cms.gov\/newsroom\/fact-sheets\/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026"},{"key":"10.1016\/j.ahj.2025.07.072_bib0024","unstructured":"CMS releases 2025 medicare part d bid information and announces premium stabilization demonstration | CMS [cited 2025 June 11];Available from: https:\/\/www.cms.gov\/newsroom\/fact-sheets\/cms-releases-2025-medicare-part-d-bid-information-and-announces-premium-stabilization-demonstration#_ftn1"},{"key":"10.1016\/j.ahj.2025.07.072_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2014.09.014","article-title":"Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke","volume":"169","author":"Navar-Boggan","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2025.07.072_bib0026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MLR.0000000000000341","article-title":"Assessing Medicare part D claim completeness using medication self-reports: the role of veteran status and generic drug discount programs","volume":"53","author":"Zhou","year":"2015","journal-title":"Med Care"},{"key":"10.1016\/j.ahj.2025.07.072_bib0027","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1111\/bcp.15391","article-title":"Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN-SPIDERS","volume":"88","author":"Dalli","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2025.07.072_bib0028","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ahj.2025.07.072_bib0029","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1524-4733.2009.00543.x","article-title":"Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia","volume":"12","author":"Karve","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.ahj.2025.07.072_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223062","article-title":"Optimal threshold of adherence to lipid lowering drugs in predicting acute coronary syndrome, stroke, or mortality: a cohort study","volume":"14","author":"Zongo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2025.07.072_bib0031","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1038\/s41598-020-60799-5","article-title":"Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships","volume":"10","author":"Greenland","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ahj.2025.07.072_bib0032","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/pds.4939","article-title":"Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients","volume":"29","author":"Qin","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032500290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287032500290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:26:27Z","timestamp":1779769587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287032500290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"alternative-id":["S000287032500290X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.07.072","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicare coverage gap status, adherence to oral anticoagulation, and stroke rates in patients with atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.07.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}